Gene Therapy for Neurodegenerative Diseases

Migration, Crosslink

📖

Gene Therapy for Neurodegenerative Diseases

active

wiki page Created: 2026-04-02T07:20:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-technologies-gene-therapy

📖 Wiki Page

technology855 wordssynced 2026-04-02

Introduction

flowchart TD Gene_Therapy["Gene Therapy"] -->|"modulates"| Abnormal_Gene_Expression["Abnormal Gene Expression"] Gene_Therapy["Gene Therapy"] -->|"treats"| Spinal_Muscular_Atrophy["Spinal Muscular Atrophy"] Gene_Therapy["Gene Therapy"] -->|"treats"| Cerebral_Adrenoleukodystrophy["Cerebral Adrenoleukodystrophy"] Gene_Therapy["Gene Therapy"] -->|"treats"| ALZHEIMER_S_DISEASE["ALZHEIMER'S DISEASE"] Gene_Therapy["Gene Therapy"] -->|"treats"| PARKINSON_S_DISEASE["PARKINSON'S DISEASE"] Gene_Therapy["Gene Therapy"] -->|"treats"| AADC_Deficiency["AADC Deficiency"] Gene_Therapy["Gene Therapy"] -->|"treats"| ALS["ALS"] Gene_Therapy["Gene Therapy"] -->|"modulates"| Disease_Progression["Disease Progression"] Gene_Therapy["Gene Therapy"] -->|"involved in"| Delivery_Challenges["Delivery Challenges"] Gene_Therapy["Gene Therapy"] -->|"treats"| Cns_Diseases["Cns Diseases"] gene_therapy["gene therapy"] -->|"treats"| P53_dysfunction["P53 dysfunction"] Gene_Therapy["Gene Therapy"] -->|"treats"| Motor_Neuron_Degeneration["Motor Neuron Degeneration"] Gene_Therapy["Gene Therapy"] -->|"treats"| Amyotrophic_Lateral_Sclerosis["Amyotrophic Lateral Sclerosis"] Gene_Therapy["Gene Therapy"] -->|"treats"| Neuronal_Structural_Integrity["Neuronal Structural Integrity"] style gene_therapy fill:#4fc3f7,stroke:#333,color:#000

...

Introduction

Mermaid diagram (expand to render)

Gene therapy represents a transformative approach to treating neurodegenerative diseases by delivering therapeutic genetic material into target cells to modify disease processes at their molecular root. This technology offers the potential to address underlying genetic causes of conditions like Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS)[@gene2023][@aav2022].

Mechanism of Action

Gene therapy for neurodegenerative diseases employs several delivery strategies:

Viral Vectors

Adeno-associated viruses (AAVs): Most commonly used vectors due to their safety profile and ability to transduce both dividing and non-dividing cells. AAV vectors can deliver genes to specific brain regions through stereotactic injection[@adenoassociated2021].
Lentiviruses: Integrate into the host genome, providing long-term expression, but carry some oncogenic risk.
Adenoviruses: High cargo capacity but elicit stronger immune responses.

Non-Viral Methods

Lipid nanoparticles (LNPs): Emerging as safer alternatives with improved delivery profiles.
Electroporation: Uses electrical pulses to facilitate gene uptake.
CRISPR-based editing: Enables precise genetic modifications including gene knock-in, knock-out, and correction[@crisprcas2023].

Target Mechanisms

Gene replacement: Delivering functional copies of mutated genes (e.g., GBA for Parkinson's disease)
Gene silencing: Using RNAi or antisense oligonucleotides to reduce expression of toxic proteins
Neuroprotective factor delivery: Expressing growth factors like BDNF, GDNF, or NGF
Metabolic enzyme supplementation: Delivering enzymes to correct metabolic deficits

Advantages

Potential for disease modification: Unlike symptomatic treatments, gene therapy can target underlying disease mechanisms

Long-lasting effects: Single administration may provide years of therapeutic benefit

Precise targeting: Can be directed to specific brain regions or cell types

Treatment of genetic forms: Particularly valuable for monogenic forms of neurodegenerative diseases

Reduced treatment burden: May eliminate need for frequent dosing

Challenges

Blood-brain barrier (BBB): Most vectors cannot cross the BBB, requiring invasive direct brain delivery

Immune response: Pre-existing immunity to viral vectors can reduce efficacy

Limited cargo capacity: AAV vectors have small packaging limits (~4.7 kb)

Off-target effects: Particularly for CRISPR-based approaches

Delivery distribution: Achieving uniform coverage of target brain regions remains challenging

Safety concerns: Risk of insertional mutagenesis with integrating vectors

Cost: Currently extremely expensive, with prices exceeding $1 million per treatment

Current Development Stage

Gene therapy for neurodegenerative diseases is in various stages of clinical development:

Parkinson's Disease

AAV-GAD gene therapy (Northwest Biotherapeutics): Completed Phase II trials for advanced [PD](/diseases/parkinsons-disease)
AADC gene therapy (Paxmedica/Prenatal): In clinical trials for aromatic L-amino acid decarboxylase deficiency, with applications to [PD](/diseases/parkinsons-disease)
[GBA](/genes/gba) gene therapy: Preclinical and early clinical stages for GBA-associated [PD](/diseases/parkinsons-disease)

Alzheimer's Disease

AAV-based BACE1 silencing: Several programs have been discontinued due to safety concerns
APOE4 gene therapy: Early-stage programs aiming to deliver protective [APOE](/genes/apoe) alleles
NGF gene therapy: Clinical trials showed some promise but efficacy limited

Huntington's Disease

HTT gene silencing: Multiple programs using ASOs and AAV-delivered RNAi in clinical trials
Neuroprotective factor delivery: Delivery of [BDNF](/proteins/bdnf-protein) and other protective factors in preclinical stages

ALS

SOD1 silencing: ASO therapy for [SOD1](/genes/sod1)-linked [ALS](/diseases/amyotrophic-lateral-sclerosis) (tofersen/Biogen) approved
C9orf72 targeting: Programs addressing the most common genetic form of [ALS](/diseases/amyotrophic-lateral-sclerosis)

Companies Working on Gene Therapy

Major Pharmaceutical Companies

Biogen: Tofersen approved for SOD1-ALS, multiple programs in development
Roche: Partnering on ASO therapies for Huntington's disease
Pfizer: Investing in AAV gene therapy for CNS disorders
Novartis: Acquired AveXis for AAV gene therapy capabilities

Biotechnology Companies

Voyager Therapeutics: Multiple CNS gene therapy programs in clinical stages
Neurocrine Biosciences: Partnering on AAV-GAD for PD
Axial Therapeutics: Focused on gut-targeted gene therapy for PD
Spark Therapeutics (Roche): Pioneering AAV gene therapy for inherited retinal disease, expanding to CNS

Academic and Research Institutions

University of California: Multiple programs in gene therapy for neurodegenerative diseases
University of Pennsylvania: Leading research in AAV delivery optimization
Mass General Hospital: Clinical trials for various gene therapy approaches

Regulatory Status

As of 2024, no gene therapies have been approved specifically for neurodegenerative diseases. However:

Tofersen (Biogen) is approved for SOD1-amyotrophic lateral sclerosis
Multiple gene therapies for CNS disorders are in late-stage clinical trials
FDA and EMA have granted breakthrough therapy designation to several programs

Future Directions

Emerging Technologies

Brain shuttle technologies: Engineered antibodies enabling BBB crossing
Regulated expression systems: Allow tunable control of therapeutic gene expression
Cell-type specific promoters: Achieve precise targeting within the brain
Base editing: More precise CRISPR-based corrections without double-strand breaks

Combination Approaches

Gene therapy combined with small molecules or biologics
Multiple gene targets addressed in single vectors
Gene therapy paired with device-based delivery (e.g., focused ultrasound)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Unknown, Gene therapy for neurodegenerative diseases: progress and challenges (Nature Reviews Drug Discovery, 2023) (2023)](https://doi.org/10.1038/s41573-023-00701-4)

[Unknown, AAV gene therapy for neurological diseases (Nature Medicine, 2022) (2022)](https://doi.org/10.1038/s41591-022-01904-1)

[Unknown, Adeno-associated virus vector delivery to the brain (Molecular Therapy, 2021) (2021)](https://doi.org/10.1016/j.ymthe.2021.02.025)

[Unknown, CRISPR-Cas9 gene editing for neurodegenerative diseases (Neuron, 2023) (2023)](https://doi.org/10.1016/j.neuron.2023.01.012)

📖 View canonical wiki page →

Related Entities

technologies-gene-therapy

▸Metadataorigin_type: v1_polymorphic_backfill

slug	technologies-gene-therapy
kg_node_id	None
entity_type	technology
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-09b2c900af47
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'technologies-gene-therapy'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

148

Outgoing

205

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Gene Therapy for Neurodegenerative Diseases

Introduction

Introduction

Mechanism of Action

Viral Vectors

Non-Viral Methods

Target Mechanisms

Advantages

Challenges

Current Development Stage

Parkinson's Disease

Alzheimer's Disease

Huntington's Disease

ALS

Companies Working on Gene Therapy

Major Pharmaceutical Companies

Biotechnology Companies

Academic and Research Institutions

Regulatory Status

Future Directions

Emerging Technologies

Combination Approaches

See Also

External Links

References

💬 Discussion